RxDoctor Payments Data

Debbie Greenidge

Gerontology · Chesapeake, VANPI 1679051684

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 67 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 15 manufacturers, the largest accounting for just 23.1% — the pattern of someone who eats at a lot of different presentations.

$2,107in general payments, 2019–2025

Across 67 payments — averaging $31.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$488
  • Otsuka America Pharmaceutical, Inc.$343
  • AbbVie$296
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$228
  • Neurocrine Biosciences, Inc.$169
  • Axsome Therapeutics, Inc.$124
  • plus $460 from 9 others

What the payments were for

  • Food & beverage$2,107100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,107 in reported general payments places this provider in the 80th percentile of 130 gerontology providers in Virginia.

See all gerontology providers in Virginia

Medicare billing

Part B allowed, 2024
$5,878
Medicare patients
51
Services billed
65

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Paliperidone ErPaliperidone11$4,749
Desvenlafaxine Succinate ErDesvenlafaxine Succinate45$4,413
Ziprasidone Hcl21$3,557
Bupropion XlBupropion Hcl50$1,448
Duloxetine Hcl52$1,255
Quetiapine Fumarate35$919
Trazodone Hcl37$883
Fluvoxamine Maleate25$715
Buspirone Hcl48$713
Mirtazapine38$710
Lamotrigine50$703
Sertraline Hcl21$686
Methylphenidate Hcl19$536
Aripiprazole13$531
Escitalopram Oxalate49$493

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Almatica Pharma LLCSertraline Hcl$24$68621 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 130 gerontology providers in Virginia.

Other gerontology in Chesapeake

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →